Effect of pedunculagin investigated by non-invasive evaluation on atopic-like dermatitis in NC/Nga mice.
OBJECTIVE
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder that is becoming increasingly prevalent. Experimental animal models have been an indispensable tool for studying its pathological mechanisms and for in vivo testing of novel therapeutic approaches. AD-like lesions can be induced experimentally in NC/Nga mice. Pedunculagin, an ellagitannin purified from the Manchurian alder, Alnus hirsuta var. microphylla, Betulaceae, is a novel immunomodulator. To evaluate the effect of pedunculagin for AD-like lesions in NC/Nga mice, using clinical and non-invasive methods.


METHODS
AD-like lesions were induced in NC/Nga mice using 2,4,6-trinitrochlorobenzene (TNCB). A cream containing 0.1% or 0.5% pedunculagin was applied to the positive treatment group, and the base cream without pedunculagin was applied to the negative treatment group. The control group did not receive any kind of topical agents. We evaluated the therapeutic efficacy of pedunculagin for AD by statistical evaluation of the clinical severity score using non-invasive biomedical engineering tools before treatment, and 1 day, 3 days, 1 week, 2 weeks and 4 weeks afterwards.


RESULTS
An AD-like skin rash was successfully induced using TNCB in NC/Nga mice. The group receiving higher concentrations of pedunculagin showed faster and greater improvement.


CONCLUSIONS
Our results suggest that remedies made from natural materials like pedunculagin are now showing promise for medical applications, and many new studies are expected to explore this potential.
Lee
Onseok
O
Research Institute for Skin Image, Korea University Medical Center, Korea University College of Medicine, 97 Guro-dong gil, Guro-gu, Seoul, South Korea.
Choi
Myeunghun
M
Ha
Seunghan
S
Lee
Gunwoo
G
Kim
Jaeyoung
J
Park
Gyuman
G
Lee
Minwon
M
Choi
Youngwook
Y
Kim
Mingi
M
Oh
Chil Hwan
CH
D029661:Alnus; D000818:Animals; D003876:Dermatitis, Atopic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004431:Ear, External / Q000187:drug effects / Q000473:pathology; D047348:Hydrolyzable Tannins / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010853:Picryl Chloride / Q000633:toxicity; D010936:Plant Extracts / Q000494:pharmacology*; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology
D047348:Hydrolyzable Tannins; D010936:Plant Extracts; C013515:ellagitannin; D014302:Trinitrobenzenesulfonic Acid; D010853:Picryl Chloride